Moderna, Inc. announced that it is expanding its pipeline of innovative vaccines with three new development programs based on the clinical success of its infectious disease vaccine portfolio to date and experience with its COVID-19 vaccine.
The development programs announced are mRNA vaccine candidates against seasonal flu, HIV and the Nipah virus. Moderna also announced an expansion of its respiratory syncytial virus (RSV) vaccine program into older adults.
Moderna currently has 24 mRNA development programs in its portfolio with 13 having entered the clinic. The company’s updated pipeline can be found at www.modernatx.com/pipeline.
